Equities Analysts Set Expectations for PRE FY2026 Earnings

Prenetics Global Limited (NASDAQ:PRE) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Prenetics Global in a research report issued to clients and investors on Friday, June 13th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings of ($1.01) per share for the year. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share.

Prenetics Global Stock Performance

Shares of PRE opened at $7.01 on Monday. Prenetics Global has a 52 week low of $3.09 and a 52 week high of $11.99. The stock has a market capitalization of $85.56 million, a price-to-earnings ratio of -1.76 and a beta of 0.17. The stock has a fifty day moving average of $6.32 and a 200-day moving average of $5.53.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Thursday, June 12th. The company reported ($0.80) EPS for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. The company had revenue of $17.31 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new position in shares of Prenetics Global Limited (NASDAQ:PRE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global as of its most recent filing with the SEC. 25.01% of the stock is owned by institutional investors and hedge funds.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.